#9 Clinical Trend: Candidiasis
A new drug is likely responsible for the increase in searches for this term. Viamet Pharmaceuticals announced that the drug VT-1161 has begun phase 2b clinical testing for treatment of recurrent vulvovaginal candidiasis. Having shown efficacy as an antifungal and a favorable safety profile, the drug may soon be available to treat the 5-8% of women in their child-bearing years who experience recurrent episodes of acute vulvovaginal candidiasis.
For more in-depth clinical information, see Candidiasis.
Medscape © 2015
Cite this: Ryan Syrek. Top 10 Clinical Trends for March 2015 - Medscape - Mar 20, 2015.